Close menu




July 28th, 2022 | 13:35 CEST

BioNTech, Defence Therapeutics, Valneva - Will the fall bring a new boost?

  • Biotechnology
  • Covid19
  • vaccine
Photo credits: pixabay.com

Officials expect the Corona pandemic to intensify sharply in the fall. Already, the number of cases is rising, as is the number of hospitalizations. To be better equipped against the currently prevalent Omicron variant, BioNTech/Pfizer have specifically adapted the Comirnaty vaccine to it. Valneva's recently approved vaccine also provides good protection against Omicron through a broader immune response to its inactivated vaccine. Also involved in vaccine development is the Canadian company Defence Therapeutics. It is currently attracting attention with its cancer-fighting developments and could become a real gem.

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNTech - New Omicron vaccine filed for approval

    BioNTech, together with its US partner Pfizer, has developed a new variant of its COVID-19 vaccine that is explicitly adapted to the currently rampant Omicron variant. It is said to provide significantly better protection than the original version of the Comirnaty vaccine. The Company has now submitted applications for approval of the new vaccine variant to the US FDA and the European EMA.

    At the same time, it was announced that the US government has already ordered 105 million doses of the new vaccine at a cost of USD 3.2 billion, with an option for an additional 195 million doses. Good news for the Company currently sitting on a mountain of USD 6.8 billion in cash with another USD 14.1 billion in receivables outstanding. The Company will report the exact figures for the 2nd quarter of the current fiscal year on August 8.

    More decisive will be the outcome of patent lawsuits filed by competitors such as the Tübingen-based CureVac Group, which the Company is currently facing. Together with its American partner, the Mainz-based company is now taking aggressive action against the latter: The Company recently announced that it had filed a lawsuit with a district court in the US state of Massachusetts. In any case, analysts are positive and currently see a share price potential of over 40%.

    Defence Therapeutics - Will a new study bring about the turnaround?

    The last few months have been a tough test for investors in the Canadian biotech company Defence Therapeutics. The share lost ground disproportionately. The ADC specialists at Defence Therapeutics (ADC = Antibody Drug Conjugates, i.e. the antibody-drug combination in a "piggyback" process, similar to BioNTech's mRNA technology) opened the year with positive announcements.

    For example, the final step of the preclinical phase for the breast cancer drug candidate AccuTOX™ was initiated. To this end, Eurofins Advinus Limited, a leading contract research organization, was contracted to conduct a GLP (Good Laboratory Practice) study. The Company has since announced numerous other research collaborations. These include the HUS Comprehensive Cancer Center, Finland's largest cancer treatment center.

    Advanced in vivo studies, including a head-to-head comparison of Roche-developed T-DM1 ("Kadcyla") with AccumTM-T-DM1 developed on Defence Therapeutics' platform, or combined treatment with intratumoral injection of AccuTOX™ variants using different preclinical PDX (patient-derived xenograft) models in existing and as yet unestablished tumors, are currently taking place there.

    The results are encouraging. It turns out that the agents developed using Accum™ technology are not only capable of preventing HPV (human papillomavirus) infections but even destroying existing tumors. If these results can be verified in clinical trials and possibly even transferred to other types of cancer, this would be a milestone. The share price is likely to react accordingly. In this respect, the current weakness with a market capitalization of only CAD 68 million should be considered an interesting entry opportunity.

    Valneva - Will the approval bring the hoped-for rally?

    Shareholders of the French vaccine manufacturer Valneva also need strong nerves and staying power. The share price has fallen by more than two-thirds since the high in November last year. At least the share price stabilized at just under EUR 10 in the face of good news. At the end of June, the EMA gave the green light to approve the vaccine in the EU.

    It is thus the first true inactivated vaccine containing the complete, inactivated SARS-CoV2 virus. However, the preparation requires two adjuvants (boosters): Alum and CpG 1018. While Alum is a known aluminium salt, CpG 2018 consists of a single-stranded, short piece of DNA composed of 22 building blocks in which the nucleotides cytidine and guanosine are coupled. Utilizing the Toll-like receptor 9, this is recognized by the body as foreign DNA and thus stimulates the antibody response.

    It is doubtful whether a vaccine that uses both aluminium, which is suspected of promoting the development of certain types of cancer, and a DNA strand as an effect enhancer will be more readily accepted by vaccine skeptics than an mRNA vaccine. After all, studies have shown that Valneva's vaccine has a stronger immune response than AstraZeneca's vaccine. Also, after the third vaccination, the agent is said to be more effective against the current Omicron variant than the unadapted version of BioNTech's Comirnaty product. The analysts at First Berlin raised the price target slightly from EUR 12 to EUR 12.50. The investment recommendation thus changed to "buy".


    It should be a hot Corona autumn. At least the manufacturers of vaccines against the SARS-CoV2 virus should be pleased. After the bottoming of BioNTech shares, the paper is ready to attack again. Valneva, too, should finally get its foot off the brake again with the approval of its vaccine. Those willing to take a bigger risk should take a closer look at the share of Defence Therapeutics. The potential of the patented technologies is enormous and promises bold investors rich returns.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read

    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.

    Read